Tzipi Ozer-Armon

Lumenis Announces New Clinical Evidence for BPH Using its Patent-Protected MOSES™ Technology

Lumenis Announces New Clinical Evidence for BPH Using its Patent-Protected MOSES™ Technology

New clinical evidence of the advantages of lithotripsy treatment of benign prostatic hyperplasia (BPH) using MOSES™ Technology is being presented at the American Urological Association's (AUA) annual meeting, taking place in Chicago, May 3-6, 2019.